Table 2 Results of the intention to treat analysis and models time-varying cumulative exposure to bevacizumab during Chemotherapy Free-Interval (CFI) and overall cumulative exposure to bevacizumab (Prodige 9 reanalysis; n= 382)

Cumulative exposure during CFI

Model 1

HR [95% CI)

Model 2a

HR [95%-CI]

Model 3a

HR [95%-CIl]

Model 4a

HR [95%-CIl]

Control (ref.)

1

1

1

1

Maintenance group

1.14 [0.90–1.44]

1.45 [1.09–1.91]

–

1.68 [1.25–2.24]

Cumulative dose [1]

0.98 [0.96–0.99]

Maintenance - No dose received

0.94 [0.61–1.44]

Maintenance - T1

1.79 [1.32–2.44]

Maintenance - T2

1.23 [0.87–1.75]

Maintenance - T3

0.50 [0.30–0.83]

Standardized dose [3]

0.69 [0.58–0.83]

AIC

2208.2

2200.4

2187.2

2192.4

Global Grambsch test

0.75

0.03

0.14

0.24

Overall cumulative exposure

Model 2b

HR [95%-confidence interval]

Model 3b

HR [95%-confidence interval]

Model 4b

HR [95%-confidence interval]

Control (ref.)

1

1

1

Maintenance group

1.27 [0.98–1.63]

1.56 [1.20–2.02]

1.37 [1.07–1.77]

Cumulative dose [1]

0.99 [0.98–1.00]

Maintenance - Q1

1

Maintenance - Q2

1.58 [1.15–2.16]

Maintenance - Q3

0.92 [0.63–1.35]

Maintenance - Q4

0.50 [0.32–0.78]

Standardized dose [3]

0.76 [0.66–0.88]

AIC

2205.7

2180.5

2196.7

Global Grambsch test

0.12

0.09

0.28